Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

By K. Marr, R. Carter, F. Crippa, A. Wald, L. Corey. Clinical Infectious Diseases, 2002

1,419 citations recorded by the source corpus.

Subfields: Cell Biology, Epidemiology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/fd12621581c413460ca162476e8548893c57828e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

In Epidemiology

In Infectious Diseases

Citations in the corpus

Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. (2005, background): “An increase in the incidence of zygomycosis has been noted in several cancer centers since the mid-1990s, predating the availability of VRC [4, 12, 13].”
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007, neutral): “Although there continues to be concern over a perceived increase in both incidence and mortality of IA (43, 44, 51, 85, 132, 149, 154, 194), the overall incidence was almost 10fold lower than that of IC for the years 1996 through 2003 (Table 4).”
Epidemiology and clinical manifestations of mucormycosis. (2012, background): “0%, with the highest incidence observed in patients with graft-versus-host disease [40–46].”
Epidemiology and outcome of zygomycosis: a review of 929 reported cases. (2005, neutral): “Sex Male 605/929 (65) 330/605 (55) Female 324/929 (35) 174/324 (54) No underlying condition at time of infection, cause of infection Overall 176/929 (19) 61/176 (35) Penetrating trauma 44/176 (25) 10/44 (23) Surgery 32/176 (18) 12/32 (38) Burns 11/176 (6) 7/11 (64) Other 89/176 (51) 32/89 (36) Under”
Voriconazole treatment for less-common, emerging, or refractory fungal infections. (2003, background): “3 for patients with scedosporiosis is encouraging: published mortality rates are 80%–100%, and AmB activity against this genus is poor [38, 39].”
Aspergillus Infections in Transplant Recipients (2005, background): “Since the late 1990s, a rising frequency of isolation of Aspergillus species has been noted in large tertiary care centers (52, 187, 296).”
Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. (2009, result): “In accordance with already published data [9], we found that IFI due to Zygomycetes or other molds remains a later complication for both allogeneic and autologous HSCT recipients.”
Infections Caused by Scedosporium spp (2008, background): “Corticosteroid therapy in cases of lymphoma, autoimmune diseases, organ transplants, and bone marrow transplants (particularly those with GVHD) has been identified as another important risk factor in the development of disseminated scedosporiosis.”
Hospital Epidemiology and Infection Control in Acute-Care Settings (2011, background): “Aspergillus species are the second most common cause of health care-associated invasive fungal infections, as they tend to occur in patients with more significant immunosuppression and prolonged neutropenia (152, 202).”
Pathogenesis of mucormycosis. (2012, background): “the number of patients at risk for this deadly infection is dramatically increasing [7].”
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. (2010, result): “our cohort, which is consistent with observations from previous studies [4, 16].”
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. (2018, background): “T-cell-depleted grafts, glucocorticosteroids and other immune suppressive drugs have been identified as further risk factors for IA in the later course after haematopoietic stem cell transplantation (HSCT), even in non-neutropenic patients [166].”
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. (2008, background): “Despite effective antifungal prophylaxis, invasive mold infections, especially Aspergillus, remain an important problem after alloBMT [35].”
Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus (2004, background): “and other hyaline and dematiaceous fungi have emerged as prominent causes of morbidity and mortality worldwide (18, 50, 53 ).”